German pharmaceutical company BioNTech(BNTXmnlwingames.US) continues to risemnlwingames, up 6mnlwingames.36%, quoted at $97.9. On the news front. BioNTech will present important presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meetingmnlwingamesis updated to demonstrate progress in its multiple immuno-oncology product lines, including innovative treatments for a variety of cancers. The company's ambitious goal is to launch its first cancer immunotherapy by 2026 and gain approval for 10 cancer indications by 2030, a promising development for patients and investors.
